AI-Powered Eye Health: BigVision Medical Selected for Jiangsu Province's Major Digital Society Scenario

Recently, the Jiangsu Provincial Data Bureau announced the selection results for major digital society scenarios in Jiangsu Province for 2025.Medpark enterprise Suzhou Big Vision Medical Technology Co., Ltd. (hereinafter referred to as “Big Vision”) had its “AI Screening Scenario for Ocular Diseases” recognized as a Major Digital Society Scenario (Digital Public Services) in Jiangsu Province in 2025.。

Fundus diseases have become the leading cause of blindness in China, yet they have long been plagued by low awareness, low screening rates, and low treatment rates. To address this challenge, Big Vision, in collaboration with authoritative institutions such as the National Clinical Research Center for Ocular Diseases and the Beijing Bethune Public Welfare Foundation, has deeply participated in the “Whole-Course Management of Fundus Diseases” project and the “Research on Screening and Referral for Major Blinding Fundus Diseases.” Leveraging its independently developed fully automated artificial intelligence-enabled OCT as the core platform, Big Vision has successfully established an integrated “screening–treatment–management” model for the whole-course management of fundus diseases. As of April 2026, the two projects had collectively completed early OCT screening for more than 280,000 individuals, providing a replicable and scalable “Chinese solution” to facilitate the transition from “passive treatment” to “proactive prevention and control” of fundus diseases.

Big Vision Medical

Suzhou Big Vision Medical TechnologyCo., Ltd.Established in 2015, our R&D team brings together top AI algorithm experts and senior ophthalmology clinical specialists from both domestic and international arenas. The company pioneered the development of MIAS, a multimodal AI-based analytical and diagnostic software system for ophthalmology, and launched the world’s first “Fully Automated AI Ophthalmic OCT BV1000 Series.” In 2025, MIAS-3000 officially received Class III medical device registration approval from the National Medical Products Administration (NMPA), becoming the world’s first medically certified Class III AI-assisted diagnostic system for OCT.

The company has successively received numerous honors, including being named a “Top Performer in the Artificial Intelligence Medical Device Innovation Task Force” by the Ministry of Industry and Information Technology of China, First Prize of the “Wu Wenjun AI Technology Invention Award,” and Second Prize of the “Jiangsu Provincial Science and Technology Award.”

Looking ahead, Big Vision will continue to actively explore screening service standards for fundus diseases that align with China’s national conditions, promoting the decentralization of high-quality medical resources. Meanwhile, the company will also expand its global presence by introducing its full line of AI-powered ophthalmic devices to international markets, leveraging Chinese technological innovation to advance global eye health.